34,173,104 Shares in Invivyd, Inc. $IVVD Acquired by Jupiter Topco LLC

Jupiter Topco LLC acquired a new stake in shares of Invivyd, Inc. (NASDAQ:IVVD) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 34,173,104 shares of the company’s stock, valued at approximately $30,048,000. Jupiter Topco LLC owned approximately 11.60% of Invivyd as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Invesco Ltd. grew its position in Invivyd by 190.6% in the first quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock worth $66,000 after acquiring an additional 71,485 shares in the last quarter. AQR Capital Management LLC raised its holdings in shares of Invivyd by 2,051.0% during the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock valued at $249,000 after purchasing an additional 391,617 shares in the last quarter. Marshall Wace LLP bought a new position in shares of Invivyd during the 2nd quarter valued at $158,000. Jane Street Group LLC acquired a new stake in shares of Invivyd in the 2nd quarter valued at $147,000. Finally, Vanguard Group Inc. lifted its stake in shares of Invivyd by 46.7% in the 3rd quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company’s stock valued at $6,339,000 after purchasing an additional 1,834,970 shares during the last quarter. 70.36% of the stock is currently owned by institutional investors and hedge funds.

Invivyd Trading Up 7.2%

NASDAQ:IVVD opened at $0.96 on Friday. Invivyd, Inc. has a 1 year low of $0.53 and a 1 year high of $3.07. The firm’s fifty day simple moving average is $0.78 and its 200 day simple moving average is $1.19. The firm has a market capitalization of $284.30 million, a PE ratio of -2.92 and a beta of 0.71.

Invivyd (NASDAQ:IVVD) last released its earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%.The firm had revenue of $14.29 million for the quarter, compared to analyst estimates of $14.40 million. As a group, analysts anticipate that Invivyd, Inc. will post -0.51 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Wall Street Zen downgraded shares of Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. HC Wainwright reaffirmed a “buy” rating on shares of Invivyd in a research report on Tuesday, August 18th. Weiss Ratings downgraded Invivyd from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday. BTIG Research reissued a “buy” rating on shares of Invivyd in a report on Tuesday, July 7th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Invivyd in a research note on Thursday. Three investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Invivyd has a consensus rating of “Hold” and a consensus price target of $8.00.

Insider Activity at Invivyd

In related news, insider Jill Andersen sold 37,256 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $0.72, for a total transaction of $26,824.32. Following the completion of the transaction, the insider owned 314,480 shares of the company’s stock, valued at approximately $226,425.60. The trade was a 10.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 228,024 shares of company stock valued at $176,540 in the last 90 days. Insiders own 12.25% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.